Abstract 262P
Background
Gestational trophoblastic tumors (GTTs) are the malignant forms of gestational trophoblastic diseases. They always follow a pregnancy, most often molar. The diagnosis of TTG is based on an abnormal course of HCG (chorionic gonadotropin hormone) and / or signs of ultrasound invasion and/or histological confirmation.
Methods
it is a retrospective study of 29 cases of GTT collected at the medical oncology department of Hassan II University Hospital-Fez, over a period of 7 years from January 2010 to December 2016.
Results
The average age was 35 years old. Sixty-five percent (65%) of our patients were pauciparous. The causal pregnancy was in 83% of cases a molar pregnancy. The staging of patients revealed pulmonary metastases in 67% of cases, liver in 19% of cases, renal in 7% of cases and cerebral in 7% of cases. Nine patients (31 %) underwent hysterectomy, with postoperative chemotherapy for 8 patients. Fifty-two percent (52%) were at high risk while 48% were low risk. Low risk patients received methotrexate-based monochemotherapy, and HCG hormone became negative after an average of 6.5 cycles. High risk patients received a polychemotherapy with differents protocols used; EMA-CO, BEP, or Cisplatin-Etoposid-MTX protocol, after an average of 3.28 cycles, the HCG hormone became negative. Eighty-six percent of our patients benefited from clinical and biological monitoring. The evolution of our patients was marked by a complete clinical and biological remission in 89.65% of patients, after an average of 12 weeks. The median survival was 76.4 ± 2.7 months, after a median follow-up of 29.78 months.
Conclusions
Malignant gestational trophoblastic tumors are a rare and challenging disease with heavy psychosocial impact hat affect the young woman who has not only had a pregnancy loss but also may be faced with a life-threatening illness. More understanding of risk factors, carcinogenesis and management is required to improve the outcome of thes patients. larger studies are still needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract